UB Paderborn / Katalog / Suche / in CDI

Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A

Journal of thrombosis and haemostasis, 2015-06, Vol.13 (6), p.967-977

2015

Volltextzugriff (PDF)

Comment on: Interpreting data on inhibitor development from previously untreated patient studies, beware of premature conclusions

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-07, Vol.24 (4), p.e273-e275

Liesner, Dr R.J

2018

Volltextzugriff (PDF)

Prophylactic treatment of bleeding episodes in children <12 years with moderate to severe hereditary factor X deficiency (FXD): Efficacy and safety of a high‐purity plasma‐derived factor X (pdFX) concentrate

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-11, Vol.24 (6), p.941-949

2018

Volltextzugriff (PDF)

Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-05, Vol.24 (3), p.344-347

2018

Volltextzugriff (PDF)

A phenotype–genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom

Journal of thrombosis and haemostasis, 2012-09, Vol.10 (9), p.1792-1801

2012

Volltextzugriff (PDF)

Extended half‐life pegylated, full‐length recombinant factor VIII for prophylaxis in children with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-03, Vol.23 (2), p.238-246

2017

Volltextzugriff (PDF)

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation

British journal of haematology, 2006-06, Vol.133 (6), p.591-605

2006

Volltextzugriff (PDF)

Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq®) in children with severe haemophilia A: efficacy, safety and pharmacokinetics

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-03, Vol.22 (2), p.232-239

2016

Volltextzugriff (PDF)

Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-07, Vol.20 (4), p.e280-e286

2014

Volltextzugriff (PDF)

Factors affecting the Haemophilia Joint Health Score in children with severe haemophilia

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-07, Vol.19 (4), p.626-631

2013

Volltextzugriff (PDF)

Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-01, Vol.22 (1), p.72-80

2016

Volltextzugriff (PDF)

Plasma and albumin‐free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients

Journal of thrombosis and haemostasis, 2008-08, Vol.6 (8), p.1319-1326

2008

Volltextzugriff (PDF)

Cerebral venous sinus thrombosis in children: risk factors, presentation, diagnosis and outcome

Brain (London, England : 1878), 2005-03, Vol.128 (3), p.477-489

2005

Volltextzugriff (PDF)

The haemtrack home therapy reporting system: Design, implementation, strengths and weaknesses: A report from UK Haemophilia Centre Doctors Organisation

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-09, Vol.23 (5), p.728-735

2017

Volltextzugriff (PDF)

Vaccinations are not associated with inhibitor development in boys with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-03, Vol.24 (2), p.283-290

2018

Volltextzugriff (PDF)

Long‐term tolerability, immunogenicity and efficacy of Nuwiq® (human‐cl rhFVIII) in children with severe haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-07, Vol.24 (4), p.595-603

2018

Volltextzugriff (PDF)

The incidence, risk and functional outcomes of intracranial haemorrhage in children with inherited bleeding disorders at one haemophilia center

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-07, Vol.22 (4), p.556-563

2016

Volltextzugriff (PDF)

First‐line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-09, Vol.23 (5), p.654-659

2017

Volltextzugriff (PDF)

How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-07, Vol.21 (4), p.444-450

2015

Volltextzugriff (PDF)

Factor XIII – an under diagnosed deficiency – are we using the right assays?

Journal of thrombosis and haemostasis, 2010-11, Vol.8 (11), p.2478-2482

2010

Volltextzugriff (PDF)

Using routine Haemophilia Joint Health Score for international comparisons of haemophilia outcome: standardization is needed

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-01, Vol.22 (1), p.142-147

2016

Volltextzugriff (PDF)

Transgenic cotton and sterile insect releases synergize eradication of pink bollworm a century after it invaded the United States

Proceedings of the National Academy of Sciences - PNAS, 2021-01, Vol.118 (1), p.1

2021

Volltextzugriff (PDF)

Thrombophilia and first arterial ischaemic stroke: a systematic review

Archives of disease in childhood, 2005-04, Vol.90 (4), p.402-405

2005

Volltextzugriff (PDF)

Immunogenicity, efficacy and safety of Nuwiq® (human‐cl rhFVIII) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-03, Vol.24 (2), p.211-220

2018

Volltextzugriff (PDF)

The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-03, Vol.21 (2), p.219-226

2015

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A

Comment on: Interpreting data on inhibitor development from previously untreated patient studies, beware of premature conclusions

Prophylactic treatment of bleeding episodes in children <12 years with moderate to severe hereditary factor X deficiency (FXD): Efficacy and safety of a high‐purity plasma‐derived factor X (pdFX) concentrate

Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee

A phenotype–genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom

Extended half‐life pegylated, full‐length recombinant factor VIII for prophylaxis in children with severe haemophilia A

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation

Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq®) in children with severe haemophilia A: efficacy, safety and pharmacokinetics

Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry

Factors affecting the Haemophilia Joint Health Score in children with severe haemophilia

Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

Plasma and albumin‐free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients

Cerebral venous sinus thrombosis in children: risk factors, presentation, diagnosis and outcome

The haemtrack home therapy reporting system: Design, implementation, strengths and weaknesses: A report from UK Haemophilia Centre Doctors Organisation

Vaccinations are not associated with inhibitor development in boys with severe haemophilia A

Long‐term tolerability, immunogenicity and efficacy of Nuwiq® (human‐cl rhFVIII) in children with severe haemophilia A

The incidence, risk and functional outcomes of intracranial haemorrhage in children with inherited bleeding disorders at one haemophilia center

First‐line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties

How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access

Factor XIII – an under diagnosed deficiency – are we using the right assays?

Using routine Haemophilia Joint Health Score for international comparisons of haemophilia outcome: standardization is needed

Transgenic cotton and sterile insect releases synergize eradication of pink bollworm a century after it invaded the United States

Thrombophilia and first arterial ischaemic stroke: a systematic review

Immunogenicity, efficacy and safety of Nuwiq® (human‐cl rhFVIII) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study

The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison

Suchergebnisse filtern